Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Adult Solid Neoplasm 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Solid Neoplasm 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Osteolysis 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Childhood Solid Neoplasm 1Carcinoma, Renal Cell 1Breast Neoplasms 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

cediranib 3Cisplatin 3Pemetrexed 2rilotumumab 1belinostat 1Sorafenib 1Semaxinib 1Platinum 1Gemcitabine 1Gefitinib 1Erlotinib Hydrochloride 1Bevacizumab 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solitary Fibrous Tumor, Pleural × ARQ 197 × Clear all
NCT01861301 2016-10-24

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

National Cancer Institute (NCI)

Phase 2 Terminated
18 enrolled 7 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡